# US 2014/0194450 A1 · Topical treatment for chemotherapy induced eyelash loss or hypotrichosis using prostamide f2 alpha agonists

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2014/0194450 A1
- Document ID: US20140194450A1
- Status: Published application
- Kind: A1
- Application number: 13/738,766
- Filed: 2013-01-10
- Published: 2014-07-10
- Earliest claimed: 2013-01-10
- Assignees: Allergan, Inc.
- Applicants: Allergan, Inc.
- Inventors: Gurpreet Ahluwalia; Frederick C. Beddingfield; Sydney G. Edwards; Scott M. Whitcup
- Web page: https://patentgrep.com/patent/US20140194450A1

## CPC

- A61K 31/5575: having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
- A61K 31/473: ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
- A61K 31/506: not condensed and containing further heterocyclic rings
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention is directed to compositions and methods for the treatment of post-chemotherapeutic hypotrichosis. More specifically, the present invention is directed to the use of compositions comprising bimatoprost for the treatment of post-chemotherapeutic hypotrichosis which may be applied before, during and after receiving chemotherapeutic treatment.

## Claims

### Claim 1

1) A method of growing eyelashes in chemotherapy patients, the method comprising applying 0.03% w/v bimatoprost to the eyelids before, during, or after chemotherapeutic treatment.

### Claim 2 (depends on 1)

2) The method of claim 1, wherein the 0.03% bimatoprost is applied at least once a day.

### Claim 3 (depends on 1, 2)

3) The method of claims 1 and 2, wherein the method results in eyelashes which are longer, thicker or darker compared to patients receiving no treatment.

### Claim 4 (depends on 2)

4) The method of claim 2, wherein the method is applied for at least 6 months after completing chemotherapeutic treatment.

### Claim 5 (depends on 4)

5) The method of claim 4, wherein the method is applied for at least 12 months after completing chemotherapeutic treatment.

### Claim 6 (depends on 3)

6) The method of claim 3, wherein the number of eyelashes increases in comparison to post-chemotherapeutic patients who received no treatment.

### Claim 7 (depends on 1)

7) The method of claim 1, wherein the bimatoprost is added during and after post-chemotherapeutic treatment.

### Claim 8 (depends on 2)

8) The method of claim 2, wherein the method is applied twice a day.

### Claim 9 (depends on 8)

9) The method of claim 8, wherein the bimatoprost is applied to the upper and lower eyelid margin of each eye.

### Claim 10 (depends on 1)

10) The method of claim 1, wherein the method effectively treats post-chemotherapeutic hypotrichosis.

### Claim 11 (depends on 1)

11) The method of claim 1, further comprising the step of administering one selected from the group consisting of Minoxidil® and Propecia®.

### Claim 12 (depends on 1)

12) The method of claim 1, wherein the method results in lower incidence of conjunctival hyperemia, punctate keratitis, erythema of the eyelid, eye pruritis and skin hyperpigmentation than in patients receiving 0.03% w/v bimatoprost for treatment of idiopathic hypotrichosis.

### Claim 13

13) A method of preventing loss of eyelashes in patients undergoing chemotherapy, the method comprising applying 0.03% w/v bimatoprost to the eyelids before, during, or after chemotherapeutic treatment.

### Claim 14 (depends on 14)

14) The method of claim 14, wherein the 0.03% bimatoprost is applied at least once a day.

### Claim 15 (depends on 14)

15) The method of claim 14, wherein the method results in eyelashes which are longer, thicker and darker compared to patients receiving no treatment.

### Claim 16 (depends on 14)

16) The method of claim 14, wherein the method is applied for at least 6 months after completing chemotherapeutic treatment.

### Claim 17 (depends on 14)

17) The method of claim 14, wherein the method is applied for at least 12 months after completing chemotherapeutic treatment.